Wire · opportunities
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
Kazia Therapeutics is expanding its paxalisib clinical trial to include HR+/HER2- advanced breast cancer, supported by preclinical data showing the drug’s strong safety profile and ability to resensitize tumors resistant to standard therapies. The trial will evaluate paxalisib combined with fulvestrant and palbociclib versus standard-of-care, with patient enrolment expected to begin by the end of 2026.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face a clearer opening to target HR+/HER2- breast cancer earlier in therapy resistance with paxalisib’s unique epigenetic action. This trial expansion could shift patient selection and treatment timing in this large breast cancer segment.
◆ Coverage
1 source · 1 Sep 2026
◆ Related on Wire
◆ Topics